ライフサイエンスコーパス: LACI

1 LACI independent impact on outcome was incremental to th

2 LACI was defined as the ratio of LA to LV end-diastolic

3 LACI was overall 5.06 (3.50-8.10) and increased with eac

4 TICIPANTS: The Lacunar Intervention Trial-2 (LACI-2) was an investigator-initiated, open-label, blind

5 index and tissue-doppler-imaging a' allowed LACI calculation as (left atrial volume index)/(tissue-d

6 e modeling, excess mortality appeared around LACI=6 and steeply increased thereafter (5-year survival

7 l volumetric/mechanical coupling measured by LACI in routine practice integrates the influence of sev

8 hazard ratio, 1.41 [1.23-1.61], P<0.0001 for LACI 6).

9 Adjusted models for LACI and DeltaLACI showed improvement in model discrimin

10 stment for traditional risk factors, greater LACI and DeltaLACI were independently associated with AF

11 F and cardiovascular disease at baseline had LACI assessed with cardiac MRI at baseline and 10 years

12 Hence, LACI is a novel and critical measure in heart failure wi

13 At diagnosis, higher LACI was independently determined by more severe FMR and

14 About outcome, higher LACI is strongly, independently, and incrementally assoc

15 ndex (LACI) and average annualized change in LACI (hereafter, DeltaLACI) measured by cardiac MRI to p

16 LACI]) and coupling change (annual change in LACI) were strong predictors for atrial fibrillation (AF

17 e of a left atrioventricular coupling index (LACI) and average annualized change in LACI (hereafter,

18 atrial volumetric/mechanical coupling index (LACI) may be useful, but large outcome data are lacking.

19 pling (left atrioventricular coupling index [LACI]) and coupling change (annual change in LACI) were

20 ipoprotein-associated coagulation inhibitor (LACI-D1) using multivalent M13 III display and derived p

21 ipoprotein-associated coagulation inhibitor (LACI-D1, also known as tissue-factor pathway inhibitor-I

22 ls were used to evaluate the associations of LACI and average DeltaLACI with incident AF.

23 olving five positions near the P1 residue of LACI-D1) and its pKAL-biased derivative, Lib#4 (allowing

24 ultivariable comprehensive adjustment showed LACI strong association with excess mortality (adjusted

25 ith Ki = 2 nM (at least 500-fold better than LACI-D1) and with high specificity.

26 st binder and > or = 12 500-fold better than LACI-D1.

27 These results show that the LACI-2 trial was feasible and ISMN and cilostazol were w

28 We varied LACI-DI iteratively in two regions: the P1 region (posit

29 eased thereafter (5-year survival 72 1% with LACI<6 and 49 2% with LACI 6, P<0.0001).

30 ar survival 72 1% with LACI<6 and 49 2% with LACI 6, P<0.0001).